Opioid Addiction | Access and Reimbursement | US | 2018

The opioid addiction market is dominated by opioid receptor agonist therapies for the maintenance treatment of opioid addiction, most notably generic methadone and Indivior’s Suboxone Film. The opioid addiction market is set to shift as Suboxone Film succumbs to generic competition while two new buprenorphine depot formulations, Indivior’s Sublocade and Braeburn/Camurus’ CAM-2038, are expected to launch.  In this content, DRG assesses how U.S. physicians and payers will react to expanding generics and premium-priced depot therapies.

QuestionsAnswered

• What is the current reimbursement landscape of key branded and generic opioid addiction therapies? What are the reasons that some branded agents (e.g., Indivior’s Suboxone Film) have preferred status over other brands (e.g., BioDelivery Sciences’ Bunavail)? Which cost-control measures are commonly employed by payers? What impact does pharmacoeconomic analysis have on the formulary decisions of opioid addiction therapies?
• Which market access factors are most influential in a physician’s choice of opioid addiction treatment? How restrictive are cost-control measures when prescribing opioid addiction therapies? How will the launch of generic versions of Suboxone Film impact prescribing of buprenorphine/naloxone sublingual film?
• What measures, if any, have payers taken to improve patient access to opioid addiction therapies? Do payers anticipate coverage changes to opioid addiction therapies in the next year?
• What access and reimbursement challenges will emerging buprenorphine depot therapies face? What cost-containment measures are payers likely to apply to Indivior’s Sublocade and Braeburn/Camurus’ CAM-2038?

Product Description

Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.

Markets covered: United States.

Primary research:

• Survey of 102 psychiatrists in the United States.
• Survey of 34 U.S. managed care organizations (MCO) pharmacy and medical directors (PDs/MDs).

Key companies: Alkermes, BioDelivery Sciences International, Braeburn Pharmaceuticals, Camurus, Indivior, Mallinckrodt, and Orexo.

Key drugs:Sublocade, CAM-2038, Suboxone Film, Zubsolv, Bunavail, Probuphine, Vivitrol, Subutex, and Methadose.

Content highlights:

• Reimbursement and contracting.
• Access and prescribing.
• Special topics.
• Opportunities and challenges for emerging therapies.